# Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

> **NCT01856426** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 28 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** EDP239
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01856426
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-11
- **Final completion:** 2015-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856426, "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01856426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*